Impact of Inflammatory Cytokine Gene Polymorphisms on Developing Acute Graft-versus-Host Disease in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Table 1
Association between clinical variable and aGvHD.
Tot. = 117
%
GVHD I–IV
GVHD II–IV
GVHD III-IV
Tot. = 73
%
Tot. = 48
%
P
Tot. = 13
%
Sex
Recipient
M
82
70.0%
48
58.5%
0.21
32
39.0%
0.54
7
8.5%
0.20
F
35
30.0%
25
71.4%
16
45.7%
6
17.1%
Donor
M
73
62.3%
47
64.3%
1.00
31
42.4%
0.70
9
12.3%
0.76
F
44
37.7%
26
59.0%
17
38.6%
4
9.0%
Underlying disease
Leukemia and lymphoma
81
69.2%
50
61.7%
0.33
36
44.4%
0.47
8
9.8%
0.28
Solid tumors
17
14.5%
13
76.4%
5
29.4%
1
5.8%
Nononcologic disease
19
16.3%
10
52.6%
7
36.8%
4
21.0%
Transplantation type
Matched, related
43
36.8%
25
58.1%
0.74
17
39.5%
0.91
4
9.3%
0.37
Matched, unrelated
47
63.8%
30
63.8%
20
42.5%
4
8.5%
Mismatch, unrelated
27
23.0%
18
66.6%
12
44.4%
5
18.5%
Conditioning regimen
TBI-based
22
18.9%
16
72.7%
0.33
13
59.0%
0.10
3
13.6%
0.70
BU-based
95
81.1%
57
60.0%
35
36.8%
10
10.5%
Stem cells sources
Bone marrow
92
78.6%
60
65.2%
0.025
41
44.5%
0.17
7
7.6%
0.003*
PBSC
25
21.4%
13
52.0%
7
28.0%
6
24.0%
GVHD prophylaxis
CSA only
33
28.2%
19
57.5%
0.52
11
33.3%
0.30
2
6.0%
0.34
CSA + other
84
71.8%
54
64.2%
37
44.0%
11
13.0%
Number of HSCT
1
101
86.3%
62
61.3%
0.78
40
39.6%
0.58
11
10.8%
1.00
>1
16
23.7%
11
68.5%
8
50.0%
2
12.5%
M: male; F: female; yrs: years; TBI: total body irradiation; BU: busulfan; GVHD: graft versus host disease; CSA: cyclosporine A; PBSC: peripheral blood stem cells; * < 0.05.